11 and 15%, respectively; P=0.0001), heterosexual (56, 16 and 20%, respectively; P=0.0001) and Black African (45, 9 and 13%, respectively;

P=0.0001) than either late starters or ideal starters. As would be expected from the way the groups were defined, there was a significantly shorter time between first presentation and starting HAART for late presenters compared with the other two groups (medians 0.1, 4.9 and 3.3 years, respectively; P=0.0001). Median follow-up after starting HIF inhibitor HAART was slightly longer among late starters (median 3.6 years) than either late presenters (3.4 years) or ideal starters (2.9 years; P=0.0001). In terms of initial regimen, the majority of patients in all groups started two NRTIs with an NNRTI (Table 1). The proportions of late presenters, late starters and ideal starters commencing a boosted PI-based regimen were 21, 19 and 17%, respectively (P=0.003). Patient disposition at 48 and 96 weeks is described in Figure 1. By 48 weeks, 86.4, 88.0 and 80.4% of late presenters, late starters and ideal starters remained under follow-up, respectively (P=0.0001). Most were receiving antiretroviral therapy (81.1% of all patients and 95.3% of those remaining under follow-up, with no major differences between late presenters and late starters) and 81.7 and 84.9% of those

on antiretroviral therapy had a viral load and CD4 cell count measurement, respectively, selleck inhibitor Selleck LBH589 within the week 40–56 window. By 96 weeks, 82.2, 83.2 and 81.5% of late presenters, late starters and ideal starters, respectively, who were alive and under follow-up at week 48 remained under follow-up (P=0.63). Again, most were on antiretroviral therapy (77.8% of those under

follow-up at week 48; 94.6% of those alive and under follow-up at week 96), and 81.0 and 83.1% of those on antiretroviral therapy at this time had a viral load and CD4 cell count in the week 88–104 window, respectively. Proportions with viral suppression to <50 copies/mL at 48 weeks were 82.4% for late presenters, 85.5% for late starters and 89.3% for ideal starters (P=0.0001). By multivariable analysis (adjusted for gender, mode of infection, ethnicity, age, calendar year, AIDS status and initial regimen), the difference between virological outcomes in late presenters and late starters was not significant at week 48, although there was a marginally nonsignificant difference in virological outcome between late starters and ideal starters (Table 2); by 96 weeks, the differences were further reduced and remained nonsignificant. The median CD4 cell count increase at 48 weeks was significantly lower for late presenters (161 cells/μL) than for late starters (206 cells/μL); while there remained a significant difference in CD4 count increase between the two groups at 96 weeks, this difference was reduced.